|
About Some Unbearable Side Effects, Observed in our Patients Treated with Angiotensin Converting Enzime (ACE-inhibitors) |
|
N.
Bakradze, M. Gelashvili, Kh. Didebeli, E. Tsatsanashvili, L. Kandelaki, O.
Togonidze |
|
ACE-inhibitors are distinguished by their effectiveness and high tolerability, but recent literatry data show that in some cases ACE-inhibitors may cause troublesome side effects. Taking
into consideration all mentioned above the purpose of our work was to
study the possibility for the development of side effects, caused by
ACE-inhibitors, that were subjectively unbearable or so troublesome that
it became necessary to stop their administration. The work was carried out at the War Veteran’s Clinical Hospital of Georgia. Effect of ACE-inhibitors of all generations - Captopril, Enalapril, Ramipril, Lisinopril, Perindopril and Phosinopril – was studied in 210 hypertensive patients – 110 males and 100 females. The age of patients ranged from 45 to 85rs. The study lasted for 12-16 weeks. Captopril was used 40 cases, Enapril and Ramipril – in 35/35, Lisinopril – in 50 and Perindopril and Phosinopril in 25/25 cases. 35 hypertensive patients not treated with ACE-inhibitors comprised the control group. The results obtained were as follows: due to unbearable side effects administration of ACE-inhibitors was stopped in 12 out of 210 patients (5,7%): in 4 Captopril (10%); 3/3 – Enalapril (Ramipril (8,5%); 3 – Lizinopril (6%) treated patients. No case of drug cessation wasobserved in Physinopril and Pirindopril treated patients. Cessation
of ACE-inhibitors in 10 out of 12 cases resulted from unbearable and
troublesome persistent expiratory dry cough and in 2 cases - by
angioneorotic aedema. Angioneorotic aedema was observed only in patients
treated with Captopril.
|
|
Literature: 1.
Преображенский
Д.В.,
Сидоренко Б.А.,
Батиралиев
Т.А. Ингибитори
АПФ и АТ1-блокаторы
в
клинической
практике.
Москва, 2002. 2.
Преображенский
Д.В.,
Сидоренко Б.А.
Побочние
еффекты АПФ-ингибиторов
и АТ1-ангиотензинових
рецептов.
Кардиология,
3, 2002, стр.
88-94. 3.
Bakris
G.L., Gilles T.D., Weber M.A., Clinical efficary and safety profiles of
AT1- receptor antagonists.
Cardiovasc Rev Rep, 1999, 20:2:1 – 19. 4.
Pylypchluk
G.B.
ACF inhibitor
versus angiotenzin II blokes – viduced cough and angioedema Ann.
Pharmacother 1999, 32:10:1060 –1066.
|